4.7 Review

Gout: why is this curable disease so seldom cured?

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 71, Issue 11, Pages 1765-1770

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2012-201687

Keywords

-

Categories

Funding

  1. Menarini Group
  2. Ardea Biosciences
  3. Ipsen
  4. Menarini
  5. Novartis
  6. Savient
  7. Abbott
  8. Roche
  9. UCB
  10. Biocryst
  11. Fidia
  12. Merck
  13. Pfizer

Ask authors/readers for more resources

Gout is the most common inflammatory arthritis and one in which pathogenesis and risk factors are best understood. One of the treatment objectives in current guidelines is 'cure'. However, audits show that only a minority of patients with gout receive adequate advice and treatment. Suboptimal care and outcomes reflect inappropriately negative perceptions of the disease, both in patients and providers. Historically, gout has been portrayed as a benign and even comical condition that is self-inflicted through overeating and alcohol excess. Doctors often focus on managing acute attacks rather than viewing gout as a chronic progressive crystal deposition disease. Urate-lowering treatment is underprescribed and often underdosed. Appropriate education of patients and doctors, catalysed by recent introduction of new urate-lowering treatments after many years with no drug development in the field, may help to overcome these barriers and improve management of this easily diagnosed and curable form of potentially severe arthritis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available